ST-01 (Saillant Therapeutics)

ST-01 is a preclinical small molecule antiviral drug candidate being developed by Saillant Therapeutics. It utilizes a novel therapeutic approach by targeting an unspecified 'cellular master regulator' to control adaptive functions within cells and tissues. The mechanism involves the selective inhibition of intracellular functional protein expression. In the context of viral infections, ST-01 halts the production of viral proteins within host cells, thereby inhibiting replication across a broad spectrum of viruses, including SARS-CoV-2 (COVID-19), Dengue, Zika, and Ebola. The ST-01 platform represents a generic virus-inhibiting therapy designed to be applicable to various viral diseases regardless of the specific virus type.

Other names

ST-01 (antiviral lead)ST-01 platformST01 platformST 01 platform